Physician profile
James Delmore
NPI 1184735508
$852.26
in general payments reported to CMS, 2019-2025
10 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $41.71 · 2021: $131 · 2022: $30.56 · 2023: $157 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $392.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $178.86 | 2019 | |
| Glaxosmithkline, LLC. | $143.65 | 2023-2025 | Jemperli, Zejula |
| Myriad Genetic Laboratories, INC. | $114.08 | 2021 | |
| Intuitive Surgical, INC. | $100.32 | 2019-2020 | |
| Baxter Healthcare | $94.75 | 2025 | Perclot |
| Merck Sharp & Dohme LLC | $86.86 | 2020-2025 | Keytruda, Lynparza |
| Abbvie INC. | $42.99 | 2025 | |
| Tersera Therapeutics LLC | $36.58 | 2023 | Zoladex |
| Eisai INC. | $30.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.61 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Delmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.